ArticlePeerJ2026

Efficacy and safety of pyrotinib-based regimens in patients with HER2-positive stage III/IV breast cancer: a real-world retrospective study in China.

Limin Zhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.